enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merck (MRK) Keytruda Advanced Gastric Cancer Study ... - AOL

   www.aol.com/news/merck-mrk-keytruda-advanced...

   Other than gastric cancer, Keytruda is approved for the treatment of many cancers globally. Keytruda sales are gaining from continued strong momentum in metastatic indications, including in some ...

3. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...

4. Merck Reports Progress On The Cancer Front As It ... - AOL

   www.aol.com/merck-reports-progress-cancer-front...

   With strong sales of its blockbuster immune-based cancer drug, Keytruda, along with vaccine products, Merck reported revenue rose 9% YoY to $15.78 billion, surpassing LSEG’s estimate of $15.20 ...

5. Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In ...

   www.aol.com/news/mercks-keytruda-phase-3-trial...

   Merck has an extensive clinical development program evaluating Keytruda in gastrointestinal cancers, which includes KEYNOTE-811 in first-line advanced HER2-positive gastric cancer, KEYNOTE-585 in ...

6. Checkpoint inhibitor - Wikipedia

   en.wikipedia.org/wiki/Checkpoint_inhibitor

   It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]

7. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33]

8. Merck Pulls Plug On Two Keytruda Late-Stage Studies On ... - AOL

   www.aol.com/merck-pulls-plug-two-keytruda...

   Thursday, Merck & Co Inc (NYSE:MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in ...

9. Merck's Keytruda Secures First FDA-Approval For Rare Form ...

   www.aol.com/mercks-keytruda-secures-first-fda...

   The approval marks the first indication for Keytruda in MPM in the U.S. Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study. MPM is a rare ...